Novo Inks $2.6B License For Once-Weekly GLP-1 Pill
By Jamie Lennox ( September 29, 2026, 4:50 PM BST) -- Novo Nordisk said Tuesday that it will pay Hengrui Pharma up to $2.6 billion for the right to market a GLP-1 weight loss pill that patients could potentially take just once per week....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.